VP Clinical Operations
AccessDx Laboratory
Houston, Texas, United States
Houda Hachad, Pharm. D, M. Res.
Dr. Hachad received her Pharmacy Doctorate and Master of Research in Drug Metabolism and Clinical Pharmacology from the Henri Poincaré, University in Nancy, France.
In 2000, Dr. Hachad joined the University of Washington, School of Pharmacy and co-developed two knowledge-based technologies managed by the University’s Center for Commercialization (CoMotion). Her group created a revenue-based model for drug-drug interactions and pharmacogenetic databases (DIDB). The DIDB platform was recently acquired by Certara to support over 200 life science and regulatory agencies.
In 2013, Dr. Hachad co-founded Translational Software, a healthcare technology company aimed at accelerating clinicians’ adoption of personalized medicine. As the Chief Science Officer, she was responsible for establishing the scientific strategy for the company and creating a pharmacogenetic knowledge base for clinical decision support.
In 2020, she joined Aranscia as the Vice President of Clinical Operations for their portfolio of brands 2bPrecise, AccessDx Laboratory, and SinguLab. As part of the clinical division, she leads several clinical initiatives to expand precision medicine turnkey solutions across portfolio companies. She brings years of expertise and enables healthcare organizations through best practices to successfully launch and expand their genomics programs. Dr. Hachad is a scientific advisory board member for the Clinical Pharmacogenetics Implementation Consortium (CPIC). She is involved with several pharmacogenomics working groups and committees aimed at standardizing pharmacogenomic testing modalities and facilitating their adoption by the clinical community.
Disclosure information not submitted.
Panel Discussion: AMP Working Group: Standardization of Pharmacogenomics Alleles
Saturday, November 18, 2023
1:45 PM - 2:15 PM MST